. 2016 May 24;21(7):872–884. doi: 10.1038/mp.2016.74

Table 2. Pharmacogenetic studies on MPH drug available for meta-analysis.

Genes	Location	Polymorphisms	Authors	Populations	Sample size		Dosages	Duration times	Results	Eligibility	Reasons
					^R	NR /PL
SLC6A3	3′UTR	40 bp VNTR	Kooij et al.⁶⁶	Netherlands	16	26	0.5 mg kg⁻¹ per day; 1 mg kg⁻¹ per day	3 Weeks	No	Included
			Contini et al.⁶⁷	Brazil	136	35	0.3 mg kg⁻¹ per day	4 Weeks	No	Included
			Mick et al.⁶⁸	Boston	66	40	0.5 mg kg⁻¹ per day; 1 mg kg⁻¹ per day	6 Weeks	No	Excluded	Placebo arm
	5′UTR	rs2652511	Contini et al.⁶⁷	Brazil	136	35	0.3 mg kg⁻¹ per day	4 Weeks	No	Excluded	Another polymorphism
	Intron 8	30 bp VNTR	Contini et al.⁶⁷	Brazil	136	35	0.3 mg kg⁻¹ per day	4 Weeks	No	Excluded	No enough studies

Abbreviations: NR, no responders; PL, placebo (Mick et al.⁶⁸); R, responders; SLC6A3, dopamine transporter; UTR, untranslated region; VNTR, variable tandem repeat polymorphism.

The results indicating no mean absence of association.